Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Forward-Looking Statements Gyre Pharmaceuticals acquired avatrombopag under a transfer agreement with Nanjing Healthnice Pharmaceutical Technology Co., Ltd. ("Nanjing Healthnice") in June 2021. Avatrombopag is an oral thrombopoietin receptor agonist ("TPO-RA"). Avatrombopag was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adults with CLD-associated TP in May 2018, and its indication was subsequently expanded to include the treatment of immune thrombocytopenia in June 2019. ...